These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 21166508)
21. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. Wei XX; Fong L; Small EJ Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270 [TBL] [Abstract][Full Text] [Related]
22. Prostate cancer vaccines. Michael A; Relph K; Annels N; Pandha H Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665 [TBL] [Abstract][Full Text] [Related]
23. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Beer TM; Bernstein GT; Corman JM; Glode LM; Hall SJ; Poll WL; Schellhammer PF; Jones LA; Xu Y; Kylstra JW; Frohlich MW Clin Cancer Res; 2011 Jul; 17(13):4558-67. PubMed ID: 21558406 [TBL] [Abstract][Full Text] [Related]
24. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Thara E; Dorff TB; Pinski JK; Quinn DI Maturitas; 2011 Aug; 69(4):296-303. PubMed ID: 21621934 [TBL] [Abstract][Full Text] [Related]
25. The evolving role of immunotherapy in prostate cancer. Gerritsen WR Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924 [TBL] [Abstract][Full Text] [Related]
26. Sipuleucel-T: Prototype for development of anti-tumor vaccines. Carballido E; Fishman M Curr Oncol Rep; 2011 Apr; 13(2):112-9. PubMed ID: 21243538 [TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Harzstark AL; Small EJ Expert Opin Biol Ther; 2007 Aug; 7(8):1275-80. PubMed ID: 17696825 [TBL] [Abstract][Full Text] [Related]
31. Integration of immunotherapy into the management of advanced prostate cancer. Kantoff P; Higano CS Urol Oncol; 2012; 30(5 Suppl):S41-7. PubMed ID: 23040162 [TBL] [Abstract][Full Text] [Related]
32. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Mulders PF; De Santis M; Powles T; Fizazi K Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563 [TBL] [Abstract][Full Text] [Related]
35. Sipuleucel-T and immunotherapy in the treatment of prostate cancer. Dawson NA; Roesch EE Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782 [TBL] [Abstract][Full Text] [Related]
36. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Patel PH; Kockler DR Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343 [TBL] [Abstract][Full Text] [Related]
37. Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches. Arlen PM Oncology (Williston Park); 2011 Mar; 25(3):261-2. PubMed ID: 21548469 [No Abstract] [Full Text] [Related]
38. Prostate cancer vaccines: current status and future potential. Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705 [TBL] [Abstract][Full Text] [Related]
39. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Sonpavde G; Di Lorenzo G; Higano CS; Kantoff PW; Madan R; Shore ND Eur Urol; 2012 Apr; 61(4):639-47. PubMed ID: 22036643 [TBL] [Abstract][Full Text] [Related]
40. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. Hall SJ; Klotz L; Pantuck AJ; George DJ; Whitmore JB; Frohlich MW; Sims RB J Urol; 2011 Sep; 186(3):877-81. PubMed ID: 21788048 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]